This pilot clinical trial studies how well magnetic resonance imaging (MRI) and positron emission tomography (PET) work in diagnosing cognitive and brain changes in older patients with cancer that has spread into surrounding healthy tissue and who are undergoing chemotherapy. Analyzing thinking abilities and brain images before and after chemotherapy may help doctors identify people at risk for cognitive side effects of the treatment and better understand effects of treatment on brain structure and function.
Additional locations may be listed on ClinicalTrials.gov for NCT02290834.
Locations matching your search criteria
United States
Massachusetts
Boston
Massachusetts General Hospital Cancer CenterStatus: Temporarily closed to accrual
Contact: Michael Parsons
Phone: 617-724-8770
PRIMARY OBJECTIVES:
I. To confirm negative effects of chemotherapy on cognition in older adults with cancer.
II. To identify imaging biomarkers of chemotherapy induced changes in cognition.
III. To identify anatomical, functional and dynamic imaging changes in the central nervous system (CNS) following treatment with chemotherapy in older cancer patients.
SECONDARY OBJECTIVES:
I. To correlate post-therapy imaging findings with clinical status and longitudinal neurocognitive assessment.
II. To assess the effect of chemotherapy on cognition by chemotherapy regimen type.
OUTLINE:
Patients undergo cognitive assessments over 60 minutes and MRI over up to 120 minutes at baseline and at 1-2 weeks and 4-6 months after chemotherapy. Patients receive Pittsburgh compound B (PiB) intravenously (IV) and undergo PiB PET over 4-4.5 hours at baseline. Patients may also receive fluorine F18 T807 IV and undergo tau PET over 4-4.5 hours at baseline and at 4-6 months after chemotherapy.
Trial PhaseNo phase specified
Trial Typediagnostic
Lead OrganizationDana-Farber Harvard Cancer Center
Principal InvestigatorMichael Parsons